Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention
Authors:
- Imma ForzanoIFImma Forzano
- Domenico FlorimonteDFDomenico Florimonte
- Viviana NarcisoVNViviana Narciso
- Mario Enrico CanonicoMCMario Enrico Canonico
- Domenico Simone CastielloDCDomenico Simone Castiello
- Lina ManziLMLina Manzi
- Stefano CristianoSCStefano Cristiano
- Alessandra SpinelliASAlessandra Spinelli
- Donato Maria ValloneDVDonato Maria Vallone
- Dario D’alconzoDDDario D’alconzo
- Federica SempliceFSFederica Semplice
- Roberta PaolilloRPRoberta Paolillo
Open Access
- 24 November 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8334
Abstract
Cardiovascular diseases (CVDs), including coronary artery disease (CAD), are the main causes of mortality and morbidity worldwide. The pathophysiology of CAD includes atherosclerosis, a chronic process leading to atherosclerotic plaque development. Clinical manifestations could be chronic, such as in the chronic coronary syndrome (CCS) scenario, or acute, such as acute coronary syndrome (ACS). The risk of subsequent cardiovascular (CV) events depends on the risk category defined by international guidelines. In particular, patients who have experienced a CV event requiring percutaneous coronary intervention (PCI) remain at heightened residual risk for subsequent events, despite advancements in standard-of-care strategies. Therefore, comprehensive residual risk management is essential in this population to mitigate ischemic risk. Secondary prevention includes different targets of treatments—hypertension, dyslipidemia, diabetes mellitus, body weight control, smoking habit reduction, and healthy lifestyle promotion. Nevertheless, there is a critical, unmet need for therapeutic strategies for this high-risk population. Growing evidence shows that atherogenic lipids and vascular inflammation drive residual risk after PCI, despite guideline-directed therapy. This review summarizes more recent evidence about secondary prevention focusing on optimal medical therapy (OMT), targeting lipids and inflammation for patients undergoing PCI.Keywords
This publication has 220 references indexed in Scilit:
- Oral Muvalaplin for Lowering of Lipoprotein(a)JAMA, 2025
- Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2024
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2023
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial InfarctionJAMA, 2022
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA, 2020
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular DiseaseJAMA, 2019
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart DiseaseJAMA, 2019
- Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary SyndromeJAMA, 2018
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceJAMA, 2016
- Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular DiseaseArchives of internal medicine (1960), 2012